Nicotinamide compounds useful as kinase modulators

1. A compound having Formula (I):

or stereoisomers or pharmaceutically acceptable salts thereof, wherein:

X is N; and Y is CR 2 ;

G is

a cyclic group selected from 1- to 2-ring carbocyclyl, 1- to 2-ring aryl, 1- to 2-ring heterocyclyl, and 1- to 2-ring heteroaryl, each substituted with zero to 3 R f ;

R 1 is H or —OR a ;

R 2 is H, —OCH 3 , halo, —CH 3 , —CF 3 , —OCF 3 , or —CN;

R 3 is H or —CH 3 ;

R 6 is H, alkoxy, halo, —CH 3 , —CF 3 , —OCF 3 , or —CN;

one of R 4 and R 5 is H, halo, —CH 3 , —CF 3 , —CN, —NH 2 , —OH, alkoxy, —OCF 3 , —NR d R d , —NR b S(O) 2 (alkyl), —NR b S(O) 2 (aryl), —NR b C(O)(phenyl), —NR b C(O)NR b (phenyl), —S(O) 2 (C 1-4 alkyl), —NR b S(O) 2 (heterocyclyl), —NR b S(O 2 )(C 1-4 haloalkyl), —NR b S(O) 2 (fluorophenyl), —NR b S(O) 2 (biphenyl), —NR b S(O) 2 (heteroaryl), —NR b S(O) 2 (benzyl), —N(S(O) 2 (C 1-4 haloalkyl)) 2 , pyrrolidine-2,5-dione, —NR b C(O)O(alkyl) or -L-C(O)-A;

and the other of R 4 and R 5 is:

a) H, halo, —CN, or alkoxy;

b) -L-A; or

c) -L-C(O)-A;

wherein L is a bond or —(CR c R c ) t —; and A is selected from A 1 , A 2 , and A 3 , wherein:

A 1 is alkyl or cycloalkyl, each independently substituted with 0 to 5 substituents independently selected from —OH, ═O, alkyl, —OH, alkoxy, —C(O)(alkyl), —C(O)OR d , —NR d R d , —C(O)NR d R d , —C(O)NR b (hydroxyalkyl), —C(O)NR b (heterocyclyl), —C(O)NR b (CR b R b ) q NR d R d , and/or —NR b C(O)(alkyl);

A 2 is heterocyclyl or heteroaryl having 1- to 3-heteroatoms independently selected from N, O, and/or S, and substituted with zero to 5 substituents independently selected from —OH, ═O, alkyl, hydroxyalkyl, cycloalkyl, —C(O)(alkyl), —NR d R d , —C(O)NR d R d , —C(O)NR b (hydroxyalkyl), —C(O)NR b (cycloalkyl), —C(O)NR b (CR b R b ) q NR d R d , —C(O)NR b (phenyl), —NR b C(O)(alkyl), —C(O)O(alkyl), and/or —C(O)O(benzyl);

A 3 is —OH, alkoxy, —NR d R d , di-(C 1-2 alkyl) N-oxide, —NR b (hydroxyalkyl), —NR b (cycloalkyl), —NR b (CR b R b ) q NR d R d , —NR b (phenyl), —NR b C(O)(alkyl), —S(alkyl), —S(O) 2 (alkyl), —S(O) 2 (fluoroalkyl), —S(O) 2 NR d R d , —S(O) 2 (CR b R b ) q NR d R d , —O(CR b R b ) q CR b (alkoxy) 2 , —O(CR b R b ) q NR b (cycloalkyl), —O(CR b R b ) q NR d R d , —NR b S(O) 2 (alkyl), —NR b S(O) 2 (aryl), —NR b S(O) 2 (heteroaryl), —NR b C(O)NR b A 2 , —NR b C(O)A 2 , —NR b A 2 , —NR b C(O)(CR b R b ) q A 2 , or —O(CR c R c ) q A 2 ;

R a is H, alkyl, hydroxyalkyl, or —(CH 2 ) n phenyl, wherein said phenyl in turn is substituted with zero to 4 R h ;

each R b is independently H and/or —CH 3 ;

each R c is independently H, —OH, —CH 3 , F, and/or —CH 2 OH;

each R d is independently H and/or alkyl;

each R f is independently H, Q 1 , R g , —C(O)Q 2 , —C(O)(CR b R b ) t Q 2 , —C(O)NR b Q 2 , —C(O)N(Q 2 ) 2 , —NR b Q 2 , —NR b CR b R b Q 2 , —N(Q 2 ) 2 , —(CR b R b ) t Q 2 , —(CR b R b ) t NR b C(O)Q 2 , —C(O)NR b (CR b R b ) t Q 2 , —NR b S(O) 2 Q 2 , —NR b S(O) 2 Q 2 , —(CR b R b ) t NR b Q 2 , and/or 5- to 6-membered heterocyclyl substituted with 0-3 R g ;

each R g is independently Q 2 , ═O, ═CR b R b , —OH, halo, —CN, alkyl, hydroxyalkyl, haloalkyl, aminoalkyl, phenyl, phenoxy, alkoxy, aryl, heteroaryl, heterocyclyl, —NR d R d , —C(O)(alkyl), —C(O)CR b R b (phenyl), —CR b R b C(O)(phenyl), and/or —C(O)NR d R d ; and/or two R g together with the carbon atom to which they are attached form a 5- to 7-membered cycloalkyl or heterocyclyl ring substituted with zero to 2 substituents independently selected from —OH, alkyl, cycloalkyl, halo, fluoroalkyl, ═O, 1- to 2-ring aryl, and/or 1- to 2-ring heteroaryl

each Q 1 is independently:

a) H, —OH, —C(O)OR d , —C(O)NR b (phenyl), —C(O)NR b (alkyl phenyl), —OC(O)(phenyl), —O(phenyl), phenyl, —NR d R d , —NR b (pyrimidinyl), —N(pyrimidinyl) 2 , hydroxyalkyl, aminoalkyl, —(CR b R b ) q C(O)O(alkyl), —(CR b R b ) q NR b C(O)O(alkyl), indolyl, imidazolidinonyl, and/or pyrrolidinonyl;

b) —NR d C(O)-Q 2 ;

c) —NR b C(O)(CR b R b ) t -Q 2 ;

d)

 wherein each R s is independently selected from alkyl, fluoroalkyl, halo, —OH, —C(O)(alkyl), —NR b C(O)(alkyl), —C(O)OR d , alkoxy, fluoroalkoxy, —NR d R d , —S(O) 2 (alkyl), —NR b C(O)O(alkyl), phenoxy, —CR b R b NR b C(O)(alkyl), and/or a cyclic group independently selected from aryl, heteroaryl, and/or heterocyclyl, wherein said cyclic group is substituted with zero or more substituents independently selected from alkyl, —OH, halo, haloalkyl, —NR d R d , alkoxy, ═O, and/or —CN;

e) —NR b S(O) 2 -Q 2 ;

f) —(CR b R b ) t C(O)-Q 2 ;

g) —NR b C(O)NR b -Q 2 ; and/or

h) —(CR b R b ) t C(O)NR b -Q 2 ;

each Q 2 is independently:

a) H, —OH, alkyl, haloalkyl, —NR d R d , alkoxy, phenoxy, and/or benzophenonyl;

b) cycloalkyl, aryl, heterocyclyl, and/or heteroaryl, each of which is substituted with zero or more substituents independently selected from alkyl, fluoroalkyl, cycloalkyl, halo, —CN, —OH, ═O, —NR d R d , alkoxy, fluoroalkoxy, —C(O)(alkyl), —C(O)O(alkyl), phenoxy, —O(cycloalkyl), —NR b C(O)(alkyl), —S(alkyl), —S(O) 2 (alkyl), —NR b C(O)O(alkyl), —CR b R b NR b C(O)(alkyl), and/or a cyclic group independently selected from aryl, heteroaryl, and/or heterocyclyl, wherein said cyclic group is substituted with zero or more substituents independently selected from alkyl, —OH, halo, —NR d R d , alkoxy, ═O, —CN, and/or haloalkyl; and/or

c) —(CR b R b ) q N(alkyl) 2 , —(CR b R b ) q (aryl), and/or —(CR b R b ) q (heteroaryl);

each R h is independently —OH, —NH 2 , alkyl, halo, haloalkyl, alkoxy, and/or haloalkoxy;

n is zero, 1, 2, 3, 4, 5, or 6;

each q is independently 1, 2, and/or 3;

each t is independently 1, 2, 3, and/or 4; and

w is zero, 1, 2, or 3.

2. The compound according to claim 1 or stereoisomers or pharmaceutically acceptable salts thereof, wherein:

G is:

i) 1- to 2-ring heteroaryl or 1- to 2-ring heterocyclyl substituted with zero to 3 substituents independently selected from alkyl, phenyl, —NR d R d , —NR d C(O)O(alkyl), —C(O)(alkyl), —C(O)(phenyl), and/or —C(O)(benzyl);

ii)

 wherein W is CR b (OR b ), C═CR b R b , NR d , or NC(O)CR b R b (phenyl); or W is CR g R g and

a) each R g is halo; or

b) R g and R g together with the carbon atom to which they are attached, form a 5- to 7-membered cycloalkyl or heterocyclyl ring substituted with zero to 2 substituents independently selected from —OH, alkyl, cycloalkyl, halo, —CF 3 , ═O, —C(O)OH, —C(O)(C 1-6 alkyl), 1- to 2-ring aryl, and/or 1- to 2-ring heteroaryl;

iii) naphthalenyl; or phenyl substituted with zero to 3 substituents independently selected from —OH, alkyl, fluoroalkyl, halo, —CN, —NR b R b , —C(O)OH, alkoxy, —CR b R b O(alkyl), —CH 2 NR b C(O)(alkyl), —CH 2 NR b C(O)(phenyl), —C(O)(alkyl), —C(O)(heterocyclyl), phenoxy, —C(O)O(alkyl), —C(O)NR b (alkyl), —C(O)N(alkyl) 2 , —C(O)NR b CR b R b (heteroaryl), —NR b S(O) 2 (alkyl), —NR b S(O) 2 (phenyl), —NR b C(O)(phenyl), —NR b C(O)(alkyl phenyl), and/or —NR b C(O)NR b (phenyl); or

iv)

v) cycloalkyl or cycloalkenyl substituted with zero to 2 substituents independently selected from —OH, halo, —CF 3 , ═O, —OC(O)(phenyl), —NR b C(O)(phenyl), —NR b CR b R b (methoxyphenyl), —NR b C(O)NR b (thiazolyl),

vi)

Q 3 is H, —C(O)O(C 1-4 alkyl), —C(O)NR b (C 1-4 alkyl), or —C(O)NR b (1-ring heteroaryl);

each R d is independently H and/or C 1-6 alkyl;

m is 1 or 2; and

v is 1 or 2.

3. The compound according to claim 2 or stereoisomers or pharmaceutically acceptable salts thereof, wherein:

R a is H, C 1-6 alkyl, C 1-6 hydroxyalkyl, or —(CH 2 ) n phenyl, wherein said phenyl in turn is substituted with zero to 4 R h ;

one of R 4 and R 5 is H, halo, —CH 3 , —CF 3 , —CN, —NH 2 , —OH, C 1-3 alkoxy, —OCF 3 , —C(O)NR b (C 1-2 alkyl), —NR b (C 1-2 alkyl), —NR b S(O) 2 (C 1-2 alkyl), —NR b S(O) 2 (phenyl), —NR b C(O)(phenyl), pyrrolidine-2,5-dione, —NR b C(O)NR b (phenyl), —NR b S(O) 2 (pyrrolidinyl), —S(O) 2 (C 1-4 alkyl), —NR b S(O) 2 (C 1-4 alkyl), —NR b S(O) 2 (fluorophenyl), —NR b S(O) 2 (biphenyl), —NR b S(O) 2 (naphthalenyl), —NR b S(O) 2 (imidazolyl), —NR b S(O) 2 (chlorothiophenyl), —NR b S(O) 2 (benzyl), —NR b S(O) 2 (pyridinyl), —NR b (S(O) 2 (C 1-4 haloalkyl), —N(S(O) 2 (C 1-4 haloalkyl)) 2 , or —NR b C(O)O(C 1-4 alkyl);

and the other of R 4 and R 5 is:

a) H, halo, —CN, or C 1-6 alkoxy;

b) -L-A; or

c) -L-C(O)-A;

wherein L is a bond or —(CR c R c ) t —; and A is selected from A 1 , A 2 , and A 3 , wherein:

A 1 is C 1-6 alkyl or C 5-7 cycloalkyl, each independently substituted with 0 to 3 substituents independently selected from —OH, —NH 2 , C 1-3 alkoxy, —C(O)NH 2 , —C(O)(C 1-6 alkyl), —C(O)OR b , —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , —C(O)NR b (C 1-6 alkyl), —C(O)NR b (C 1-6 hydroxyalkyl), —C(O)NR b (heterocyclyl), —NR b C(O)(C 1-6 alkyl), —C(O)NR b (CR b R b ) q NH(C 1-6 alkyl), and/or —C(O)NR b (CR b R b ) q N(C 1-6 alkyl) 2 ;

A 2 is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl having 1- to 3-heteroatoms independently selected from N, O, and/or S, and substituted with zero to 4 substituents independently selected from —OH, ═O, C 1-6 alkyl, C 1-4 -hydroxyalkyl, C 3-6 cycloalkyl, —C(O)(C 1-6 alkyl), —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , —C(O)NR b (C 1-6 alkyl), —C(O)NR b (C 1-6 hydroxyalkyl), —C(O)NR b (C 3-6 cycloalkyl), —C(O)NR b (CR b R b ) q NH(C 1-6 alkyl), —C(O)NR b (phenyl), —C(O)NR b (CR b R b ) q N(C 1-6 alkyl) 2 , —C(O)NR b R b , —NR b C(O)(C 1-6 alkyl), —C(O)O(C 1-4 alkyl), and/or —C(O)O(benzyl);

A 3 is —OH, —NH 2 , C 1-6 alkoxy, —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , di-(C 1-2 alkyl) N-oxide, —NR b (C 1-6 hydroxyalkyl), —NR b (C 3-7 cycloalkyl), —NR b (CR b R b ) q NH(C 1-6 alkyl), —NR b (CR b R b ) q N(C 1-6 alkyl) 2 , —NR b (phenyl), —NR b C(O)(C 1-6 alkyl), —S(C 1-6 alkyl), —S(O) 2 (C 1-6 alkyl), —S(O) 2 (C 1-4 fluoroalkyl), —S(O) 2 NR d R d , —S(O) 2 (CR b R b ) q N(C 1-2 alkyl) 2 , —O(CR b R b ) q CR b (C 1-2 alkoxy) 2 , —O(CR b R b ) q NR b (C 3-6 cycloalkyl), —O(CR b R b ) q N(C 1-2 alkyl) 2 , —NR b C(O)NR b A 2 , —NR b C(O)A 2 , —NR b A 2 , —NR b C(O)(CR b R d ) q A 2 , or —O(CR c R c ) q A 2 ;

G is:

i) 1- to 2-ring heteroaryl or 1- to 2-ring heterocyclyl substituted with zero to 3 substituents independently selected from —OH, ═O, C 1-6 alkyl, —CR b R b C(O)OH, —CR b R b C(O)O(C 1-4 alkyl), —CR b R b C(O)NH(phenyl), —CR b R b S(O) 2 (phenyl), phenyl, —NR b (C 1-6 alkyl), —N(C 1-6 alkyl)C(O)O(C 1-6 alkyl), —C(O)(C 1-4 alkyl), —C(O)(phenyl), and/or —C(O)(benzyl);

ii)

 wherein W is CR b (OR b ), C═CR b R b , NH, N(C 1-6 alkyl), or NC(O)CR b R b (phenyl); or W is CR g R g and

a) each R g is halo; or

b) R g and R g together with the carbon atom to which they are attached, form a 5- to 7-membered cycloalkyl or heterocyclyl ring substituted with zero to 2 substituents independently selected from —OH, —C(O)OH, —C(O)(C 1-4 alkyl), C 1-6 alkyl, C 3-6 cycloalkyl, halo, —CF 3 , ═O, 1- to 2-ring aryl, and/or 1- to 2-ring heteroaryl;

iii) naphthalenyl; or phenyl substituted with zero to 3 substituents independently selected from —OH, C 1-6 alkyl, C 1-4 fluoroalkyl, halo, —CN, —NR b R b , C 1-4 alkoxy, —C(O)OH, —CR b R b O(C 1-6 alkyl), —CH 2 NR b C(O)(C 1-6 alkyl), —CH 2 NR b C(O)(phenyl), —C(O)(C 1-6 alkyl), —C(O)(heterocyclyl), phenoxy, —C(O)O(C 1-6 alkyl), —C(O)NR b (C 1-6 alkyl), —C(O)N(C 1-6 alkyl) 2 , —C(O)NR b CR b R b (heteroaryl), —NR b S(O) 2 (C 1-6 alkyl), —NR b S(O) 2 (phenyl), —NR b C(O)(phenyl), —NR b C(O)(C 1-6 alkyl phenyl), and/or —NR b C(O)NR b (phenyl); or

iv)

v) C 3-6 cycloalkyl or C 4-6 cycloalkenyl substituted with zero to 2 substituents independently selected from —OH, halo, —CF 3 , ═O, —OC(O)(phenyl), —NR b C(O)(phenyl), —NR b CR b R b (methoxyphenyl), —NR b C(O)NR b (thiazolyl),

vi)

Q 1 is:

a) H, —OH, —C(O)OR b , —C(O)NR b (phenyl), —C(O)NR b (C 1-6 alkyl phenyl), —OC(O)(phenyl), —O(phenyl), phenyl, —NR b R b , —NR b (pyrimidinyl), —N(pyrimidinyl) 2 , C 1-4 hydroalkyl, C 1-4 aminoalkyl, —(CR b R b ) q C(O)O(C 1-4 alkyl), —(CR b R b ) q NR b C(O)O(C 1-4 alkyl), indolyl, imidazolidinonyl, or pyrrolidinonyl;

b) —NR b C(O)-Q 2 ;

c) —NR b C(O)CR b R b -Q 2 ;

d)

 wherein each R s is independently selected from C 1-6 alkyl, C 1-6 fluoroalkyl, halo, —OH, —C(O)(C 1-6 alkyl), —NR b C(O)(C 1-6 alkyl), —C(O)O(C 1-6 alkyl), C 1-6 alkoxy, C 1-6 fluoroalkoxy, —NR b R b , —N(C 1-6 alkyl) 2 , —S(O) 2 (C 1-6 alkyl), —NR b C(O)O(C 1-6 alkyl), phenoxy, —CR b R b NR b C(O)(C 1-6 alkyl), and/or a cyclic group independently selected from aryl, heteroaryl, and/or heterocyclyl, wherein said cyclic group is substituted with zero or more substituents independently selected from C 1-6 alkyl, —OH, halo, C 1-2 haloalkyl, —NR b R b , C 1-4 alkoxy, ═O, and/or —CN;

e) —NR b S(O) 2 -Q 2 ; or

f) —NR b C(O)NR b -Q 2 ;

Q 2 is:

a) H, C 1-6 alkyl, C 1-6 haloalkyl, —N(C 1-6 alkyl) 2 , C 1-6 alkoxy, phenoxy, or benzophenonyl;

b) C 3-7 cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is substituted with zero or more substituents independently selected from C 1-6 alkyl, C 3-7 cycloalkyl, halo, —CN, —OH, ═O, —NR b R b , C 1-6 fluoroalkyl, C 1-6 alkoxy, —S(C 1-6 alkyl), —C(O)(C 1-6 alkyl), —C(O)O(C 1-6 alkyl), —O(C 3-7 cycloalkyl), C 1-6 alkylphenyl, hydroxyphenyl, halophenyl, (C 1-6 fluoroalkyl)phenyl, and/or pyridinyl; or

c) —(CR b R b ) q N(C 1-6 alkyl) 2 , —(CR b R b ) q (phenyl), or —(CR b R b ) q (furanyl); and

each R h is independently —OH, —NH 2 , C 1-6 alkyl, halo, C 1-6 haloalkyl, C 1-6 alkoxy, and/or C 1-6 haloalkoxy.

4. The compound according to claim 3 , or stereoisomers or pharmaceutically acceptable salts thereof,

R 6 is H or C 1-2 alkoxy;

one of R 4 and R 5 is H, halo, C 1-2 alkoxy, —C(O)NR b (C 1-2 alkyl), —NR b (C 1-2 alkyl), —NR b S(O) 2 (C 1-2 alkyl), —NR b S(O) 2 (phenyl), —C(O)NH(C 1-2 alkyl), —N(CH 3 )C(O)(phenyl), pyrrolidine-2,5-dione, —NR b C(O)NR b (phenyl), —CH 2 S(O) 2 (pyrrolidinyl), —S(O) 2 (C 1-2 alkyl), —NR b S(O) 2 (C 1-2 alkyl), —NR b S(O) 2 (fluorophenyl), —NR b S(O) 2 (biphenyl), —NR b S(O) 2 (naphthalenyl), —NR b S(O) 2 (imidazolyl), —NR b S(O) 2 (chlorothiophenyl), —NR b S(O) 2 (benzyl), —NR b S(O) 2 (pyridinyl), —NR b (S(O) 2 (C 1-4 chloroalkyl), —N(S(O) 2 (C 1-4 chloroalkyl)) 2 , or —NR b C(O)O(C 1-4 alkyl);

and the other of R 4 and R 5 is:

a) H, halo, —CN, or C 1-2 alkoxy;

b) -L-A; or

c) -L-C(O)-A;

wherein L is a bond or —(CR c R c ) t —; and A is selected from A 1 , A 2 , and A 3 , wherein:

A 1 is C 1-4 alkyl or C 5-7 cycloalkyl, each independently substituted with 0 to 2 substituents independently selected from —OH, —NH 2 , C 1-2 alkoxy, —C(O)(C 1-6 alkyl), —C(O)OR b , —NH(C 1-4 alkyl), —N(C 1-6 alkyl) 2 , —C(O)NR b (C 1-6 alkyl), —C(O)NR b (C 1-6 hydroxyalkyl), —C(O)NR b (heterocyclyl), —C(O)NR b (CR b R b ) q NH(C 1-6 alkyl), —C(O)NR b (CR b R b ) q N(C 1-6 alkyl) 2 , and/or —NR b C(O)(C 1-6 alkyl);

A 2 is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl having 1- to 3-heteroatoms independently selected from N, O, and/or S, and substituted with zero to 4 substituents independently selected from —OH, ═O, C 1-4 alkyl, C 1-4 hydroxyalkyl, C 3-5 cycloalkyl, —C(O)(C 1-4 alkyl), —NH(C 1-4 alkyl), —N(C 1-4 alkyl) 2 , —C(O)NR b (C 1-4 alkyl), —C(O)NR b (C 1-4 -hydroxyalkyl), —C(O)NR b (C 3-4 cycloalkyl), —C(O)NR b (CR b R b ) q NH(C 1-4 alkyl), —C(O)NR b (phenyl), —C(O)NR b (CR b R b ) q N(C 1-4 alkyl) 2 , —C(O)NR b R b , —NR b C(O)(C 1-4 alkyl), —C(O)O(C 1-4 alkyl), and/or —C(O)O(benzyl);

A 3 is —OH, —NH 2 , C 1-4 alkoxy, —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , di-(C 1-2 alkyl) N-oxide, —NR b (C 1-4 -hydroxyalkyl), —NR b (C 3-6 cycloalkyl), —NR b (CR b R b ) q NH(C 1-4 alkyl), —NR b (CR b R b ) q N(C 1-4 alkyl) 2 , —NR b (phenyl), —NR b C(O)(C 1-4 alkyl), —NR b C(O)(C 1-4 alkyl), —S(C 1-4 alkyl), —S(O) 2 (C 1-4 alkyl), —S(O) 2 (C 1-3 fluoroalkyl), —S(O) 2 NR d R d , —S(O) 2 (CR b ) q N(C 1-2 alkyl) 2 , —O(CR b R b ) q CR b (C 1-2 alkoxy) 2 , —O(CR b R b ) q NR b (C 3-6 cycloalkyl), —O(CR b R b ) q N(C 1-2 alkyl) 2 , —NR b C(O)NR b A 2 , —NR b C(O)A 2 , —NR b A 2 , —NR b C(O)(CR b R d ) q A 2 , or —O(CR c R c ) q A 2 ;

G is:

i) 1- to 2-ring heteroaryl or heterocyclyl substituted with zero to 3 substituents independently selected from —OH, ═O, C 1-6 alkyl, —CR b R b C(O)OH, —CR b R b C(O)O(C 1-4 alkyl), —CR b R b C(O)NH(phenyl), —CR b R b S(O) 2 (phenyl), phenyl, —NR b (C 1-6 alkyl), —N(C 1-6 alkyl)C(O)O(C 1-6 alkyl), —C(O)(C 1-4 alkyl), —C(O)(phenyl), and/or —C(O)(benzyl);

ii)

 wherein W is CR b (OR b ), C═CR b R b , NH, N(C 1-6 alkyl), or NC(O)CR b R b (phenyl); or W is CR g R g and

a) each R g is halo; or

b) R g and R g together with the carbon atom to which they are attached, form a 5- to 7-membered cycloalkyl or heterocyclyl ring substituted with zero to two substituents independently selected from C 1-4 alkyl, —C(O)OH, —C(O)O(C 1-4 alkyl), ═O, 1- to 2-ring aryl, and/or 1- to 2-ring heteroaryl;

iii) naphthalenyl; or phenyl substituted with zero to 3 substituents independently selected from —OH, C 1-6 alkyl, C 1-2 fluoroalkyl, halo, —CN, —NR b R b , C 1-4 alkoxy, —C(O)OH, —CR b R b O(C 1-4 alkyl), —CH 2 NR b C(O)(C 1-4 alkyl), —CH 2 NR b C(O)(phenyl), —C(O)(C 1-4 alkyl), —C(O)-(heterocyclyl), phenoxy, —C(O)O(C 1-6 alkyl), —C(O)NR b (C 1-4 alkyl), —C(O)N(C 1-4 alkyl) 2 , —C(O)NR b CR b R b (heteroaryl), —NR b S(O) 2 (C 1-4 alkyl), —NR b S(O) 2 (phenyl), —NR b C(O)(phenyl), —NR b C(O)(C 1-6 alkyl phenyl), and/or —NR b C(O)NR b (phenyl); or

iv)

v)

vi) cyclohexyl or cyclohexenyl substituted with zero to 2 substituents independently selected from —OH, ═O, —OC(O)(phenyl), —NR b C(O)(phenyl), —NR b CR b R b (methoxyphenyl), —NR b C(O)NR b (thiazolyl),

vii)

wherein Q 1 is:

a) H, —OH, —C(O)OR b , —C(O)NR b (phenyl), —C(O)NR b (C 1-6 alkyl phenyl), —OC(O)(phenyl), —O(phenyl), phenyl, —NR b R b , —NR b (pyrimidinyl), —N(pyrimidinyl) 2 , C 1-4 hydroalkyl, C 1-4 -aminoalkyl, —(CR b R b ) q C(O)O(C 1-4 alkyl), —(CR b R b ) q NR b C(O)O(C 1-4 alkyl), indolyl, imidazolidinonyl, or pyrrolidinonyl;

b) —NR b C(O)—B 1 , wherein B 1 is C 1-4 alkyl; C 1-4 alkoxy; C 3-6 cycloalkyl optionally substituted with C 1-4 alkyl or C 1-4 alkoxy; phenoxy; benzophenonyl; or 1- to 3-ring aryl optionally substituted with C 1-4 alkyl, C 1-2 fluoroalkyl, or C 1-4 alkoxy;

c) —NR b C(O)—B 2 , wherein B 2 is 1- to 2-ring heterocyclyl or heteroaryl substituted with zero or more substituents independently selected from C 1-4 alkyl, —NR b R b , halo, C 1-2 fluoroalkyl, —CN, ═O, C 1-4 alkoxy, —C(O)(C 1-4 alkyl), and/or pyridinyl;

d) —NR b C(O)CR b R b —B 3 , wherein B 3 is —N(C 1-6 alkyl) 2 , phenyl, or 1- to 2-ring heteroaryl substituted with zero or more substituents independently selected from C 1-4 alkyl, —OH, —CN, halo, and/or C 1-4 alkoxy;

e)

 wherein each R s is independently selected from C 1-6 alkyl, C 1-2 fluoroalkyl, halo, —OH, —C(O)(C 1-4 alkyl), —NR b C(O)(C 1-4 alkyl), —C(O)O(C 1-4 alkyl), C 1-4 alkoxy, C 1-4 fluoroalkoxy, —NR b R b , —N(C 1-4 alkyl) 2 , —S(O) 2 (C 1-4 alkyl), —NR b C(O)O(C 1-6 alkyl), —CR b R b NR b C(O)(C 1-6 alkyl), phenoxy, and/or a cyclic group independently selected from aryl, heteroaryl, and/or heterocyclyl, wherein said cyclic group is substituted with zero or more substituents independently selected from C 1-6 alkyl, —OH, halo, C 1-2 haloalkyl, —NR b R b , C 1-4 alkoxy, ═O, and/or —CN;

f) —NHS(O) 2 —B 4 wherein B 4 is phenyl or 1-ring heteroaryl substituted with zero to 3 substituents independently selected from C 1-4 alkyl, halo, —NR b R b , C 1-4 alkoxy, and/or C 1-2 fluoroalkyl;

g) —NR b C(O)NR b —B 5 wherein B 5 is phenyl substituted with zero to 2 substituents independently selected from halo, C 1-6 alkyl, —CN, —NR b R b , C 1-2 fluoroalkyl, C 1-4 alkoxy, —C(O)O(C 1-6 alkyl), —S(C 1-2 alkyl), —C(O)(C 1-4 alkyl), and/or —O(C 3-6 cycloalkyl);

h) —NR b C(O)NR b —B 6 wherein B 6 is a 1-ring heteroaryl substituted with zero to 2 substituents independently selected from C 1-4 alkyl, halo, C 1-4 fluoroalkyl, C 3-6 cycloalkyl, —S(C 1-3 alkyl), and/or —C(O)O(C 1-4 alkyl); or

i) —NR b C(O)NR b —B 7 wherein B 7 is C 1-6 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, —(CR b R b ) q (phenyl), or —(CR b R b ) q (furanyl); and

each R h is independently —OH, —NH 2 , C 1-6 alkyl, halo, C 1-4 haloalkyl, C 1-4 alkoxy, and/or C 1-4 haloalkoxy.

5. The compound according to claim 4 , or stereoisomers or pharmaceutically acceptable salts thereof, wherein:

R 1 is H;

R 2 is H, F, or Br;

R 6 is C 1-2 alkoxy, R 5 is H, and R 4 is H; or

R 6 is H, R 5 is halo, and R 4 is 5- to 6-membered heterocyclyl having 1- to 3-heteratoms independently selected from N, O, and/or S, and substituted with zero to 2 substituents independently selected from C 1-4 alkyl, C 1-4 -hydroxyalkyl, and/or —C(O)(C 1-4 alkyl); or

R 6 is H, R 5 is H, —OCH 3 , —NH(CH 3 ), —C(O)NHCH 3 , —N(CH 3 )C(O)(phenyl), pyrrolidine-2,5-dione, —N(CH 3 )C(O)NH(phenyl), —CH 2 S(O) 2 (pyrrolidinyl), —S(O) 2 CH 3 , —NR b S(O) 2 CH 3 , —NR b S(O) 2 CH 2 CH 3 , —NR b S(O) 2 (phenyl), —NR b S(O) 2 (fluorophenyl), —NR b S(O) 2 (biphenyl), —NR b S(O) 2 (naphthalenyl), —NR b S(O) 2 (chlorothiophenyl), —NR b S(O) 2 (imidazolyl), —NR b S(O) 2 (benzyl), —NR b S(O) 2 (pyridinyl), —NR b (S(O) 2 CH 2 CH 2 CH 2 Cl), —N(S(O) 2 CH 2 CH 2 CH 2 Cl) 2 , or —NR b C(O)O(butyl), and R 4 is:

a) H, halo, or —CN;

b) -L-A; or

c) -L-C(O)-A;

wherein L is a bond or —(CR c R c ) t —; and A is selected from A 1 , A 2 , and A 3 ; wherein:

A 1 is C 1-4 alkyl substituted with 0 to 2 substituents independently selected from —OH, —NH 2 , —OCH 3 , —C(O)OH, —NH(C 1-2 alkyl), and/or —N(C 1-2 alkyl) 2 ;

A 2 is 4- to 6-membered heterocyclyl or 5- to 6-membered heteroaryl having 1- to 3-heteroatoms independently selected from N, O, and/or S, and substituted with zero to 4 substituents independently selected from —OH, ═O, C 1-3 alkyl, C 1-2 hydroxyalkyl, C 3-4 cycloalkyl, —C(O)(C 1-2 alkyl), —C(O)O(C 1-4 alkyl), and/or —C(O)O(benzyl);

A 3 is —OH, —NH 2 , C 1-4 alkoxy, —OCH 2 CH(OCH 2 CH 3 ) 2 , —OCH 2 CH 2 NH(cyclopropyl), —OCH 2 CH 2 (pyrrolidinyl)), —OCH 2 CH 2 N(CH 3 ) 2 , N,N-dimethylethamine oxide, —NH(C 1-4 alkyl), —N(C 1-2 alkyl) 2 , —NH(C 1-2 hydroxyalkyl), —NH(C 3-6 cycloalkyl), —NH(CH 2 ) q NH(C 1-4 alkyl), —NH(CH 2 ) q N(C 1-2 alkyl) 2 , —NH(phenyl), —NHC(O)(C 1-2 alkyl), —S(C 1-4 alkyl), —S(O) 2 (C 1-4 alkyl), —S(O) 2 (C 1-2 fluoroalkyl), —S(O) 2 NR d R d , —S(O) 2 (CH 2 ) q N(C 1-2 alkyl) 2 , —NHC(O)A 2 , —NHA 2 , —NHC(O)(CH 2 ) q A 2 , or —O(CH 2 ) q A 2 ;

G is:

i) 1- to 2-ring heteroaryl or heterocyclyl substituted with zero to 3 substituents independently selected from —OH, ═O, C 1-4 alkyl, —CH 2 C(O)OH, —CH 2 C(O)NH(phenyl), —CH 2 C(O)O(C 1-2 alkyl), —CH 2 S(O) 2 (phenyl), phenyl, —NR b (C 1-4 alkyl), —N(C 1-4 alkyl)C(O)O(C 1-4 alkyl), —C(O)(C 1-4 alkyl), —C(O)(phenyl), and/or —C(O)(benzyl);

ii)

 wherein W is CH(OH), C═CH 2 , NH, N(C 1-4 alkyl), or NC(O)CR b R b (phenyl); or W is CR g R g and

a) each R g is halo; or

b) R g and R g together with the carbon atom to which they are attached, form a 5- to 6-membered cycloalkyl or heterocyclyl ring substituted with zero to two substituents independently selected from —C(O)OH, —CH(CH 3 ) 2 , —C(O)OCH 2 CH 3 , ═O, phenyl, pyridinyl, and/or naphthalenyl;

iii) naphthalenyl; or phenyl substituted with zero to 3 substituents independently selected from —OH, C 1-4 alkyl, C 1-2 fluoroalkyl, halo, —CN, —NR b R b , C 1-4 alkoxy, —CH 2 O(C 1-4 alkyl), —CH 2 NHC(O)(C 1-4 alkyl), —CH 2 NR b C(O)(phenyl), —C(O)(C 1-4 alkyl), —C(O)(heterocyclyl), phenoxy, —C(O)OH, —C(O)O(C 1-4 alkyl), —C(O)NR b (C 1-2 alkyl), —C(O)N(C 1-4 alkyl) 2 , —C(O)NR b CR b R b (furanyl), —NR b S(O) 2 (C 1-4 alkyl), —NR b S(O) 2 (phenyl), —NR b C(O)(phenyl), —NR b C(O)(C 1-4 alkyl phenyl), and/or —NR b C(O)NR b (phenyl);

iv)

v)

vi) cyclohexyl or cyclohexenyl substituted with zero to 1 substituent selected from —OH, ═O, —OC(O)(phenyl), —NHC(O)(phenyl), —NHCH(CH 3 )(methoxyphenyl), or —NHC(O)NH(thiazolyl); or

vii)

wherein Q 1 is:

a) H, —OH, —C(O)OH, —C(O)NR b (phenyl), —C(O)NR b (C 1-4 alkyl phenyl), —OC(O)(phenyl), —O(phenyl), —NR b R b , —NR b (pyrimidinyl), —N(pyrimidinyl) 2 , —CH 2 OH, —CH 2 NH 2 , —CH 2 C(O)OCH 2 CH 3 , —CH 2 NHC(O)O(butyl), —CH 2 CH 2 NHC(O)O(butyl), phenyl, indolyl, imidazolidinonyl, or pyrrolidinonyl;

b) —NHC(O)—B 1 , wherein B 1 is C 1-4 alkyl; C 1-4 alkoxy; C 3-6 cycloalkyl optionally substituted with C 1-4 alkyl or C 1-4 alkoxy; phenoxy; benzophenonyl; or 2- or 3-ring aryl optionally substituted with C 1-4 alkyl or C 1-4 alkoxy;

c) —NHC(O)—B 2 , wherein B 2 is 1- to 2-ring heterocyclyl or heteroaryl substituted with zero or more substituents independently selected from C 1-4 alkyl, —NR b R b , halo, C 1-2 fluoroalkyl, —CN, ═O, C 1-4 alkoxy, —C(O)O(C 1-4 alkyl), and/or pyridinyl;

d) —NHC(O)CH 2 —B 3 , wherein B 3 is a —N(C 1-4 alkyl) 2 , phenyl, 1- to 2-ring heteroaryl substituted with zero or more substituents independently selected from C 1-4 alkyl, —OH, —CN, halo, and/or C 1-3 alkoxy;

e)

 wherein each R s is independently C 1-4 alkyl, C 1-2 fluoroalkyl, halo, —OH, —C(O)(C 1-4 alkyl), —NR b C(O)(C 1-4 alkyl), —C(O)O(C 1-4 alkyl), C 1-4 alkoxy, —O(C 1-4 fluoroalkyl), —NH 2 , —N(C 1-4 alkyl) 2 , —S(O) 2 (C 1-2 alkyl), —NR b C(O)O(C 1-4 alkyl), —CR b R b NR b C(O)(C 1-4 alkyl), phenoxy, phenyl, 1- to 3-ring heterocyclyl, or 1- to 3-ring heteroaryl, wherein said phenyl, said heterocyclyl, and said heteroaryl are substituted with zero or more substituents independently selected from C 1-4 alkyl, —OH, halo, C 1-2 haloalkyl, —NR b R b , C 1-4 alkoxy, ═O, and/or —CN;

f) —NHS(O) 2 —B 4 wherein B 4 is phenyl or 1-ring heteroaryl substituted with zero to 3 substituents independently selected from C 1-4 alkyl, halo, —NR b R b , C 1-4 alkoxy, and/or C 1-2 fluoroalkyl;

g) —NHC(O)NH—B 5 wherein B 5 is phenyl substituted with zero to two substituents independently selected from halo, C 1-4 alkyl, —CN, —NR b R b , C 1-2 fluoroalkyl, C 1-4 alkoxy, —C(O)O(C 1-4 alkyl), —S(C 1-2 alkyl), —C(O)(C 1-4 alkyl), and/or —O(C 3-6 cycloalkyl);

h) —NHC(O)NH—B 6 wherein B 6 is 1-ring heteroaryl substituted with zero to two substituents independently selected from C 1-4 alkyl, halo, C 1-4 fluoroalkyl, C 3-6 cycloalkyl, —S(C 1-2 alkyl), and/or —C(O)O(C 1-4 alkyl);

i) —NHC(O)NH—B 7 wherein B 7 is C 1-4 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, benzyl, —CR b R b CR b R b -(phenyl), or —CR b R b -(furanyl);

each R c is independently H, —CH 3 , and/or —CH 2 OH;

each q is independently 1 or 2; and

t is 1 or 2.

6. The compound according to claim 1 , or stereoisomers or pharmaceutically acceptable salts thereof, wherein: R 3 is H.

7. The compound according to claim 1 , or stereoisomers or pharmaceutically acceptable salts thereof, wherein:

R 6 is —OCH 3 , R 5 is H, and R 4 is H; or

R 6 is H, R 5 is F, and R 4 is morpholinyl or N-methyl piperazinyl; or

R 6 is H, R 5 is —OCH 3 , and R 4 is H, —OCH 2 CH(OCH 2 CH 3 ) 2 , —OCH 2 CH 2 N(CH 3 ) 2 , —OCH 2 CH 2 NH(cyclopropyl), or —OCH 2 CH 2 (pyrrolidinyl); or

R 6 is H, R 5 is —NH(CH 3 ), —C(O)NHCH 3 , —N(CH 3 )C(O)(phenyl), pyrrolidine-2,5-dione, —N(CH 3 )C(O)NH(phenyl), —CH 2 S(O) 2 (pyrrolidinyl), —S(O) 2 CH 3 , —NR b S(O) 2 CH 3 , —NR b S(O) 2 CH 2 CH 3 , —NR b S(O) 2 (phenyl), —N(CH 3 )S(O) 2 (fluorophenyl), —N(CH 3 )S(O) 2 (biphenyl), —N(CH 3 )S(O) 2 (naphthalenyl), —N(CH 3 )S(O) 2 (imidazolyl), —N(CH 3 )S(O) 2 (chlorothiophenyl), —N(CH 3 )S(O) 2 (benzyl), —N(CH 3 )S(O) 2 (pyridinyl), —NH(S(O) 2 CH 2 CH 2 CH 2 Cl), —N(S(O) 2 CH 2 CH 2 CH 2 Cl) 2 , or —N(CH 3 )C(O)O(butyl), and R 4 is H or —C(O)(morpholinyl); or

R 6 is H, R 5 is H, and R 4 is H, F, —CN, ethyl, butyl, hydroxyethyl, dimethylaminoethyl, N,N-dimethylethamine oxide, —OCH 3 , —NHC(O)CH 3 , —NH 2 , —N(ethyl) 2 , —C(O)CH 3 , —C(O)OH, —C(O)O(butyl), —C(O)NH(cyclopropyl), —C(O)NH(butyl), —C(O)NH(phenyl), —C(O)N(CH 3 ) 2 , —C(O)N(ethyl) 2 , —C(O)NHCH 2 CH 2 N(CH 3 ) 2 , —C(O)NH(hydroxyethyl), —C(CH 3 ) 2 CH 2 OH, —C(CH 3 ) 2 C(O)OCH 2 CH 3 , —CH 2 CH 2 NH(butyl), —CH 2 CH 2 (azetidinyl), —CH 2 CH 2 (imidazolyl), —CH 2 CH 2 (pyrrolidinyl), —C(CH 3 ) 2 C(O)NH(oxetanyl), —CH 2 CH(CH 2 OH)NHC(O)(pyrrolidinyl), —CH 2 CH(CH 2 OH)NHC(O)(piperidinyl), —C(CH 3 ) 2 C(O)NHCH 2 CH 2 N(CH 3 ) 2 , —NHC(O)CH 2 (pyrrolidinyl), —C(CH 3 ) 2 C(O)NH(cyclopropyl), —C(CH 3 ) 2 C(O)NHCH 2 CH 2 OH, —S(O) 2 N(CH 3 ) 2 , —C(CH 3 ) 2 C(O)OH, —S(O) 2 CH 3 , —S(O) 2 CF 3 , —S(O) 2 CH 2 CH 2 N(CH 2 CH 3 ) 2 , pyrrolidinyl, oxazolyl, tetrahydropyranyl, morpholinyl, 4-hydroxymorpholinyl, morpholinonyl, piperidinyl, N-methyl piperidinyl, N-(butyl-OC(O))piperidinyl, 1-(ethyl-OC(O))-4-methylpiperidinyl, 1,4-dimethyl piperidinyl, N-acetyl piperazinyl, piperazinyl, N-methyl piperazinyl, N-ethyl piperazinyl, N-propyl piperazinyl, N-cyclopropyl-piperazinyl, N-cyclobutyl piperazinyl, N-(benzyl-OC(O))piperazinyl, —C(O)(azetidinyl), —C(O)(pyrrolidinyl), —C(O)(morpholinyl), —C(O)(piperidinyl), —C(O)(N-methyl piperazinyl), —C(O)(N-hydroxyethyl piperazinyl), —CH 2 (morpholinyl), —CH 2 (oxazolidinonyl),

G is:

i) thiophenyl; methylpyrrolidinyl, hydroxypyrrolidinyl, pyridinyl; indolyl; isoindolinyl;

benzofuranyl; N-methylpyrazolyl; dimethyl morpholinyl; morpholinyl optionally substituted with phenyl, —CH 2 C(O)OH, —CH 2 C(O)NH(phenyl), or —CH 2 S(O) 2 (phenyl); piperazinyl optionally substituted with ═O, —CH 2 C(O)OCH 3 , or —C(O)(benzyl); N-methyl piperazinyl substituted with —CH 2 C(O)OCH 3 ; thiazolyl substituted with —NH(propyl) or —N(propyl)(C(O)(O-butyl); or 1,2,3,4-tetrahydroisoquinolinyl substituted with zero or one substituents selected from —C(O)(phenyl), —C(O)CH 3 , or —C(O)butyl;

ii)

iii) naphthalenyl; or phenyl substituted with zero to 3 substituents independently selected from —OH, —CH 3 , propyl, F, Cl, —CF 3 , —CN, —NH 2 , C 1-3 alkoxy, —CH 2 OCH 3 , —CH 2 NHC(O)CH 3 , —CH 2 NHC(O)(phenyl), —C(O)CH 3 , —C(O)-(pyrrolidinyl), phenoxy, —C(O)OH, —C(O)O-(t-butyl), —C(O)NHCH 3 , —C(O)N(CH 3 ) 2 , —C(O)NHCH 2 (furanyl), —NHS(O) 2 (CH 3 ), —NHS(O) 2 (phenyl), —NHC(O)(phenyl), —NHC(O)(t-butyl phenyl), and/or —NHC(O)NH(phenyl);

iv)

 wherein Q 1 is:

a) H, —C(O)OH, —C(O)NH(t-butyl phenyl), —O(phenyl), —NH 2 , —NH(pyrimidinyl), —N(pyrimidinyl) 2 , —N(CH 3 )C(O)(phenyl), —CH 2 OH, —CH 2 NH 2 , —CH 2 C(O)OCH 2 CH 3 , —CH 2 NHC(O)O(butyl), —CH 2 CH 2 NHC(O)O(butyl), or indolyl;

b) —NHC(O)—B 1 , wherein B 1 is —CH 3 , propyl, cyclopropyl, cyclohexyl, butyl cyclohexyl, t-butoxy, phenoxy, benzophenonyl, naphthalenyl, methoxynaphthalenyl, or anthracenyl;

c) —NHC(O)—B 2 , wherein B 2 is piperidinyl, furanyl, morpholinyl, pyrazinyl, indolyl, benzothiazolyl, benzotriazolyl, benzimidazolyl, quinolinyl, quinolinonyl, quinoxalinyl, 2,3-dihydrobenzodioxinyl, fluorenonyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, pyridinyl, pyridazinyl, or pyrimidinyl, each of which is substituted with zero or more substituents independently selected from —CH 3 , propyl, butyl, —NH 2 , Cl, —CF 3 , —C(O)O(butyl), and/or pyridinyl;

d) —NHC(O)CH 2 —B 3 , wherein B 3 is a —N(CH 3 ) 2 , phenyl, pyridinyl, or methyl indolyl;

e)

 wherein each R s is independently —CH 3 ; butyl; —CF 3 ; halo; —OH; —C(O)CH 3 ; —NHC(O)CH 3 ; —C(O)OCH 3 ; —C(O)OCH 2 CH 3 ; —OCH 3 ; propoxy; —OCF 2 CHF 2 ; —N(CH 3 ) 2 ; —S(O) 2 CH 3 ; —NHC(O)O(butyl); —CH 2 NHC(O)(t-butyl); phenoxy; pyrrolyl; thiophenyl; pyrazolyl; imidazolyl; methyl oxadiazolyl; triazolyl; tetrazolyl; methyl tetrazolyl; pyridinyl; pyrimidinyl; pyridinonyl; N-methyl piperazinyl, indolyl, benzimidazolyl, chromenonyl, or phenyl substituted with zero or more substituents independently selected from —CH 3 , —OH, F, and/or Cl;

f) —NHS(O) 2 —B 4 wherein B 4 is phenyl, trifluoromethyl phenyl, thiophenyl, dimethyl isoxazolyl, or methyl imidazolyl;

g) —NHC(O)NH—B 5 wherein B 5 is phenyl substituted with zero to two substituents independently selected from halo, —CH 3 , ethyl, butyl, —CN, —CF 3 , —OCH 3 , —C(O)O(ethyl), —C(O)O(t-butyl), —SCH 3 , —C(O)CH 3 , and/or —O(cyclopentyl);

h) —NHC(O)NH—B 6 wherein B 6 is pyrazolyl, isoxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, or pyridinyl, each of which is substituted with zero to two substituents independently selected from —CH 3 , butyl, Br, —CF 3 , cyclopropyl, —S(ethyl), and/or —C(O)O(ethyl); or

i)-NHC(O)NH—B 7 wherein B 7 is propyl, chloroethyl, C 5-6 cycloalkyl, benzyl, —CH 2 CH 2 — (phenyl), or —CH 2 — (furanyl);

v)

 wherein Q 1 is H, —NH 2 , phenyl, —C(O)OH, —NHC(O)(t-butyl), —NHC(O)(phenyl), —NHC(O)(trifluoromethyl phenyl), —NHC(O)O(t-butyl), —C(O)NH(phenyl), —C(O)NH(t-butyl phenyl), or —NHC(O)NH(methyl thiazolyl);

vi)

 wherein Q 1 is H, —OH, —OC(O)(phenyl), —NHC(O)(phenyl), —NHCH(CH 3 )(methoxyphenyl), or —NHC(O)NH(thiazolyl); or

vii)

8. A compound having Formula (II):

or stereoisomers or pharmaceutically acceptable salts thereof, wherein:

R 1 is H or C 3 alkoxy;

Q 1 is: H, —NH 2 , —NHC(O)O-(t-butyl), —NHC(O)NH—B 8 ; and

B 8 is phenyl or thiazolyl, each of which is optionally substituted with one or two methyl groups.

9. A pharmaceutical composition, comprising; a pharmaceutically acceptable carrier and a compound of claim 1 , or stereoisomers or pharmaceutically acceptable salts thereof.

10. A method of using a compound of claim 1 , or stereoisomers or pharmaceutically acceptable salts thereof, for treatment of an allergic disorder, and/or inflammatory disease.